| In Vivo | Andarine exhibits potent and efficacious anabolic activity and results in dose-dependent stimulation of growth in prostate, seminal vesicles, and levator ani muscle with the ED50 of 0.43 mg/day, 0.55 mg/day, and 0.14 mg/day, respectively. Besides, Andarine shows no dose-dependent effect on castration-induced change in FSH, and partially suppresses LH production at dose rates of 0.5 mg/day or higher. In dogs administrated by intravenous doses of Andarine (0.1, 1, 3, and 10 mg/kg), the total body clearance (CL) ranged from 7.4 mL/min/kg to 3.1 mL/min/kg, volume of distribution at steady state (Vss) is 1.39 L/kg and half-life of Andarine is 229 minutes, respectively. In addition, oral bioavailability is 38%, 62% and 91% for the 10 mg/kg, 1 mg/kg and 0.1 mg/kg doses, respectively. Andarine demonstrates tissue-selective pharmacological activity and significantly decreased prostate weight to 79.4% at a concentration of 0.5 mg/day in intact rats. |
|---|
m.cnreagent.com